Glucocorticoids Do Not Inhibit Antitumor Activity of Activated CD8+ T Cells

Glucocorticoids are potent immunosuppressive drugs that are generally withheld from cancer patients receiving immunotherapy. We sought to test the hypothesis that glucocorticoids might interfere with the function of cells after adoptive transfer. We gave dexamethasone, a potent synthetic glucocorticoid, to B16 melanoma-bearing mice receiving the adoptive cell transfer (ACT) of pmel-1 T-cell receptor transgenic CD8+ cells. Dexamethasone caused a profound lymphodepletion but, surprisingly, did not alter the antitumor efficacy of ACT-based regimens whether given before, during, or after ACT. Although dexamethasone radically decreased the number of native CD8+ splenocytes in recipient mice, it did not affect the numbers of CD8+ pmel-1 cells derived from ACT in these mice. In vitro proliferation assays revealed acute inhibition of naive pmel-1 CD8+ cells by dexamethasone without significant effect on activated cells. In vitro interferon (IFN)-γ release from activated pmel-1 CD8+ cells showed partial inhibition by dexamethasone, but this effect was relatively minor when compared with the near-complete inhibition of naive cells. Thus, glucocorticoids had a profound inhibitory effect on naive CD8+ T cells but had little impact on the proliferation and function of activated CD8+ pmel-1 T cells. Finally, because glucocorticoids had no effect on tumor regression in this model, it may be possible to use glucocorticoids in some patients receiving ACT-based immunotherapy regimens.

[1]  N. Restifo,et al.  Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. , 2005, Current opinion in immunology.

[2]  C. Klebanoff,et al.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. , 2005, Trends in immunology.

[3]  C. Klebanoff,et al.  Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction1 , 2004, The Journal of Immunology.

[4]  S. Rosenberg,et al.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. Franchimont.  Overview of the Actions of Glucocorticoids on the Immune Response: A Good Model to Characterize New Pathways of Immunosuppression for New Treatment Strategies , 2004, Annals of the New York Academy of Sciences.

[6]  Jiho Jang,et al.  T Cell Receptor Signaling Inhibits Glucocorticoid-induced Apoptosis by Repressing the SRG3 Expression via Ras Activation* , 2004, Journal of Biological Chemistry.

[7]  Xin Chen,et al.  Differential response of murine CD4+CD25+ and CD4+CD25– T cells to dexamethasone‐induced cell death , 2004, European journal of immunology.

[8]  N. Geller,et al.  Improved survival in steroid‐refractory acute graft versus host disease after non‐myeloablative allogeneic transplantation using a daclizumab‐based strategy with comprehensive infection prophylaxis , 2004, British journal of haematology.

[9]  T. Waldmann,et al.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Steven A. Rosenberg,et al.  Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma , 2003, Journal of immunotherapy.

[11]  Steven A. Rosenberg,et al.  Adoptive-cell-transfer therapy for the treatment of patients with cancer , 2003, Nature Reviews Cancer.

[12]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[13]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Franchimont,et al.  Glucocorticoids and Inflammation Revisited: The State of the Art , 2003, Neuroimmunomodulation.

[15]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[16]  Jiang Zhu,et al.  Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. , 2002, The Journal of clinical investigation.

[17]  David F. Richards,et al.  In Vitro Generation of Interleukin 10–producing Regulatory CD4+ T Cells Is Induced by Immunosuppressive Drugs and Inhibited by T Helper Type 1 (Th1)– and Th2-inducing Cytokines , 2002, The Journal of experimental medicine.

[18]  D. Franchimont,et al.  Positive Effects of Glucocorticoids on T Cell Function by Up-Regulation of IL-7 Receptor α1 , 2002, The Journal of Immunology.

[19]  W. Almawi,et al.  Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor , 2002, Journal of leukocyte biology.

[20]  C. Riccardi,et al.  Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB. , 2001, Blood.

[21]  J. Bertoglio,et al.  Interleukin-2 inhibits glucocorticoid receptor transcriptional activity through a mechanism involving STAT5 (signal transducer and activator of transcription 5) but not AP-1. , 2001, Molecular endocrinology.

[22]  C. Orosz,et al.  REJECTION RESPONSES TO ALLOGENEIC HEPATOCYTES BY RECONSTITUTED SCID MICE, CD4 KO, AND CD8 KO MICE1,2 , 2000, Transplantation.

[23]  K. Yamamoto,et al.  Crosstalk pathway for inhibition of glucocorticoid-induced apoptosis by T cell receptor signaling. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Offringa,et al.  Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. , 2000, Blood.

[25]  J. Ashwell,et al.  Glucocorticoids in T cell development and function*. , 2000, Annual review of immunology.

[26]  C. Riccardi,et al.  Glucocorticoid hormones in the regulation of cell death. , 2000, Therapie.

[27]  C. Orosz,et al.  Patterns of immune responses evoked by allogeneic hepatocytes: evidence for independent co-dominant roles for CD4+ and CD8+ T-cell responses in acute rejection. , 1999, Transplantation.

[28]  P. Allavena,et al.  Glucocorticoids affect human dendritic cell differentiation and maturation. , 1999, Journal of immunology.

[29]  Guo-liang Yu,et al.  Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand* , 1999, The Journal of Biological Chemistry.

[30]  A. Gurney,et al.  Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR , 1999, Current Biology.

[31]  G. Szot,et al.  The role of CD8 and CD4 T cells in intestinal allograft rejection: a comparison of monoclonal antibody-treated and knockout mice. , 1999, Transplantation.

[32]  D. Green,et al.  Regulation of Fas-Ligand Expression during Activation-induced Cell Death in T Lymphocytes via Nuclear Factor κB* , 1999, The Journal of Biological Chemistry.

[33]  M. Rieder,et al.  Multiplicity of glucocorticoid action in inhibiting allograft rejection. , 1998, Cell transplantation.

[34]  B. Moss,et al.  gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand , 1998, The Journal of experimental medicine.

[35]  J. Belaiche,et al.  Effects of dexamethasone on the profile of cytokine secretion in human whole blood cell cultures , 1998, Regulatory Peptides.

[36]  J. Drouin,et al.  Antagonism between Nur77 and glucocorticoid receptor for control of transcription , 1997, Molecular and cellular biology.

[37]  C. Riccardi,et al.  A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Asada,et al.  Regulation of T Cell Apoptosis via T Cell Receptors and Steroid Receptors , 1996, Stem cells.

[39]  C. Ware,et al.  Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids , 1995, The Journal of experimental medicine.

[40]  P. Holt,et al.  Modulation of airway intraepithelial dendritic cells following exposure to steroids. , 1995, American journal of respiratory and critical care medicine.

[41]  R. Martin,et al.  Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma , 1995, The Journal of experimental medicine.

[42]  L. Schwartz,et al.  Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate–early gene nur77 , 1994, Nature.

[43]  B. Calnan,et al.  Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas , 1994, Nature.

[44]  S. Szefler,et al.  Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. , 1994, The Journal of clinical investigation.

[45]  B. Huber,et al.  IL-4 and IL-2 selectively rescue Th cell subsets from glucocorticoid-induced apoptosis. , 1992, Journal of immunology.

[46]  M. Iwata,et al.  Rescue of thymocytes and T cell hybridomas from glucocorticoid‐induced apoptosis by stimulation via the T cell receptor/CD3 complex: a possible in vitro model for positive selection of the T cell repertoire , 1991, European journal of immunology.

[47]  M. Merćep,et al.  Programmed T lymphocyte death. Cell activation- and steroid-induced pathways are mutually antagonistic. , 1990, Journal of immunology.

[48]  J. Gutterman,et al.  Increased incidence of hypersensitivity to iodine‐containing radiographic contrast media after interleukin‐2 administration , 1990, Cancer.

[49]  D. Weisdorf,et al.  Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. , 1990, Blood.

[50]  M. Nieto,et al.  IL-2 protects T cell hybrids from the cytolytic effect of glucocorticoids. Synergistic effect of IL-2 and dexamethasone in the induction of high-affinity IL-2 receptors. , 1989, Journal of immunology.

[51]  M. Nieto,et al.  IL-2 protects T lymphocytes from glucocorticoid-induced DNA fragmentation and cell death. , 1989, Journal of immunology.